Exploring regulatory data sets of the Comirnaty vaccine - 9f

Reformulating and summarising what we do not know about pharmacokinetics and indications of Cominarty

Since publishing our summary of preliminary findings on the pharmacokinetics of Comirnaty (essentially 15 questions), we have received no replies or explanations despite it becoming clear that the vaccine is still heavily promoted.

So, hopefully, to make things simpler, we summed up and shortened the questions. With a bit of luck, someone will respond.

The lipid nanoparticles (LNP) “excipients” ALC-0315 and ALC-0159 are carriers and protectors of the modmRNA they contain. In rats, they are found everywhere.

• Does this apply to humans, and if so, what happens to them or their metabolites after repeated exposures, given that previous participation in an investigational study involving lipid nanoparticles was one of the exclusion criteria in trial BNT162-01 ?

(see pdf page 20 of INTERIM CLINICAL STUDY REPORT dated 23 September 2020).

• One or more of their ingredients are considered carcinogenic.  Are the LNPs carcinogenic or toxic to human genes?

• Are the pharmacokinetics of the modmRNA encapsula…